- Home
- LXEH vs DTIL Comparison
LXEH vs DTIL Comparison
Compare LXEH & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXEH | DTIL |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 97.7M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LXEH | DTIL |
|---|---|---|
| Price | $0.22 | $4.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | ★ 709.8K | 158.4K |
| Earning Date | 01-01-0001 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 106.52 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $34.30 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.18 | $3.53 |
| 52 Week High | $50.08 | $8.82 |
Technical Indicators
Market Signals| Indicator | LXEH | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 48.25 | 63.59 |
| Support Level | $0.18 | $4.66 |
| Resistance Level | $0.28 | $5.19 |
| Average True Range (ATR) | 0.03 | 0.28 |
| MACD | -0.00 | 0.09 |
| Stochastic Oscillator | 19.20 | 76.34 |
Price Performance
Historical ComparisonAbout LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.